Positron Emission Tomography Imaging of Bone in Patients With Metastatic Prostate Cancer - A Pilot Study Evaluating Treatment Response
- Correlate pre-treatment and 3-month post-treatment carbon-11 (^11C) acetate and
fludeoxyglucose F 18 positron emission tomography (^18F-FDG PET) images with changes in
clinical response measures in patients with bone-dominant metastatic prostate cancer.
- Compare ^11C acetate and ^18F-FDG PET scanning results with bone scintigraphy in these
patients to determine which best predicts clinical response.
- Correlate changes in ^11C acetate and ^18F-FDG PET with changes in prostate-specific
- Correlate changes in ^11C acetate and ^18F-FDG PET with clinical symptom parameters
(pain scale scores and analgesic usage scales).
- Correlate ^11C acetate and ^18F-FDG PET scan response with clinical time to
- Determine if PET scan response can predict duration of progression-free survival.
OUTLINE: This is a pilot study. Patients are stratified according to hormone response
(sensitive [stratum 1] vs refractory [stratum 2]).
Patients undergo carbon-11 acetate and fludeoxyglucose F 18 positron emission tomography
imaging prior to and 3 months after initiation of either androgen-deprivation therapy
(stratum 1) or docetaxel (stratum 2).
Pain and quality of life are assessed at baseline and at 3 months.
Patients are followed every 3 months for up to 5 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Primary Purpose: Diagnostic
Correlation of pre-treatment and 3-month post-treatment carbon-11 (11C) acetate and fludeoxyglucose F 18 positron emission tomography (18F-FDG PET) images with changes in clinical response measures
Evan Y. Yu, MD
Seattle Cancer Care Alliance
United States: Institutional Review Board
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|
|University of Washington School of Medicine||Seattle, Washington 98195|